Case report: delayed response after electroconvulsive therapy in a patient with major depressive disorder

Fangyue Chen1*, Emad Sidhom2, Sharon Yang3, Eladia Ruiz-Mendoza1 and Julius Essem3

Abstract

Background: Major depressive disorder and associated mood syndromes are amongst the most common psychiatric disorders. To date, electroconvulsive therapy (ECT) is considered the most effective short-term treatment for patients with severe or treatment-resistant depression. In clinical practice, there is considerable variation in the ECT dosing schedule, with the number of sessions typically ranging from 6 to 12, with early antidepressant effects being predictive of increased positive outcomes. We describe here an unusual case of a female patient with severe depression who did not respond to ECT until the 11th session, after which she had shown a drastic improvement in her mental state.

Case presentation: A 75-year-old female presented to the old age psychiatry inpatient unit with new onset dysphoric mood, anhedonia, and severe negativity. She scored 23 on the 17-item Hamilton Rating Scale for Depression (HAM-D), and was rated 6 on Clinical Global Impression severity (CGIS) by the responsible clinician. She suffered from post-natal depression fifty years ago and was successfully treated with ECT. She was therefore initiated on a course of ECT treatment. Her condition initially deteriorated, displaying features of catatonia and psychosis, unresponsive to ECT treatment or concurrent psychotropic medications. After 11th ECT session, she started to show signs of clinical improvement and returned close to her baseline mental state after a total of 17 ECT sessions. She remained well 3 months post-treatment, scoring 4 on HAM-D, Clinical Global Improvement or change (CGI-C) rated as 1 (very much improved). The diagnosis was ICD-10 F32.3 severe depressive episode with psychotic symptoms.

Conclusions: we describe here an unusual case of delayed response to electroconvulsive therapy in the treatment of severe depressive disorder. Studies have shown the number of acute ECT treatments to be highly variable, affected by a number of factors including treatment frequency, condition treated and its severity, the ECT technical parameters, as well as concurrent use of pharmacological treatment. This may call for re-consideration of the current ECT treatment guidelines, requiring more research to help stratify and standardize the treatment regime.

Keywords: Electroconvulsive therapy, Major depressive disorder, Delayed response, Standard treatment regime

* Correspondence: Fangyue.chen@nhs.net
1Peterborough City Hospital, Bretton Gate, Peterborough, UK
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Major depressive disorder (MDD) and associated mood syndromes are amongst the most common psychiatric disorders. MDD can at times become debilitating, or at worst, life-threatening. In general, antidepressant medications can be effective in treating MDD, but they fail to achieve remission in approximately 1 in 3 patients [1].

Electroconvulsive therapy (ECT) is considered the most effective short-term treatment for patients with severe or treatment-resistant depression, with 70–90% of patients showing improvement [2]. ECT involves the application of electricity to the scalp in order to induce seizure activity [3].

There is a considerable variation in ECT dosing schedules in clinical practice. During an acute course of the treatment, ECT is given as a twice-weekly regime in the United Kingdom [4], and twice or thrice-weekly as recommended in the United States [5]. More frequent schedule may be given in situations where rapid onset of response is of prime importance. The number of sessions typically range from 6 to 12 [4]. It has been suggested that individuals with schizophrenia may need 12 to 20 sessions [6]. Rarely, some patients may be prescribed ECT as ‘continuation’ (C-ECT) or ‘maintenance’ ECT (M-ECT) to prevent relapse and recurrence, respectively [7].

The ECT handbook of the Royal College of Psychiatrists stated that clinicians may wish to reassess the need for ECT if there was no response after six sessions. If there is no response within 12 treatment sessions, it is unlikely to have a ‘sustained response to ECT’ [8].

The number of ECT sessions required to elicit improvement tends to vary depending on the intensity of ECT, where a thrice weekly regime yields faster response than twice weekly [9]. Other factors associated with a rapid response include the severity of depression and seizure Energy Index [10, 11]. The pulse width of the ECT stimulation and electrode placement have also been implicated in the speed of response [12, 13]. A few of the important factors affecting ECT efficacy are summarised in Table 1. One study had concluded that the average number of sessions required to elicit remission in depression was 10.9 (± S.D. 4.3) [14]. Another showed a 50% response rate to ECT after the 12th session [15], whilst some patients showed response to ECT after the first session [16]. To date, we are not aware that there is robust clinical evidence to support using 12 sessions as a cut-off point, apart from the legal framework of ECT. Thirtalli et al. reviewed the factors influencing the number of ECT sessions, from which no recommendations could be drawn, and the number of ECT sessions was not included as primary outcomes in the reviewed studies [17].

One of the variables predictive of increased positive outcomes is the early antidepressant effects of ECT. A study by the Consortium for Research in ECT has indicated that more than half of patients treated with ECT showed improvement after 3 sessions, and 65% achieved remission after 10 sessions [16]. Likewise, Tsuchiyama et al. 2005 reported that response by session 3 of ECT treatment predicted long-term efficacy in relieving depression [18]. On the contrary, a study examining the effectiveness of ECT in adolescents suggested that early lack of response does not necessarily predict a lack of response at the end of the ECT course, with significant clinical improvement seen after 12 sessions [19].

In this article, we outline a case of a female patient, who presented with severe depressive episode. She initially failed to respond to her ECT treatment, until the 11th session, when she had a drastic improvement in her clinical presentation.

Case presentation

A 75-year-old female patient presented to the old age psychiatry inpatient unit with a 10-week history of deteriorating depressive symptoms, triggered by a telephone scam. She had repeatedly attempted to slit her wrists with a knife, and developed concerns about

| Factors                        | Associations                                                                 | Ref.       |
|--------------------------------|------------------------------------------------------------------------------|------------|
| ECT intensity                  | Thrice weekly ECT yields faster response than twice weekly, but induced more severe memory impairment | [9]        |
| Severity of depression         | The severity of depression predicts rapid response                            | [10, 11]   |
| Presence of psychotic features | The presence of psychotic features predicts ECT remission                     | [11]       |
| Seizure energy index (SEI)     | High SEI is associated with a rapid response                                 | [10]       |
| Age                            | Older age predicts faster speed of response                                  | [11, 12]   |
| Pulse width                    | Brief pulse ECT (pulse width 1.0 ms) is associated with higher remission rates than ultrabrief pulse (pulse width 0.3 ms) | [12]       |
| Electrode placement            | Bilateral electrode placement is more efficient than alternative electrode placement | [13]       |
having cancer following two brief illnesses with infections. On admission, she presented with dysphoric mood, anhedonia, and severe negativity. She described herself as not having ‘any thoughts in my head,’ and ‘frightened.’ She showed evidence of catastrophizing, and appeared hypervigilant. Her food and fluid intake had been poor over the past 10 weeks.

In the past, she suffered from post-natal depression fifty years ago and was successfully treated with ECT. In the intervening years, she did not suffer from any episodes of severe mental illness, with no depression or mania. Physically, she suffered from hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and polymyalgia rheumatica for which she was on a reducing dose regime of prednisolone (4 mg OD on admission, reduced by 1 mg every 12 week). She was a non-smoker, and there was no history of alcohol or substance misuse. She lives with her husband and has two supportive children living nearby.

On examining her mental state, she was catatonic, displaying excessive motion intermittently including bilateral non-Parkinsonian motion of the upper limbs and lip licking. Her speech was slow and interrupted in flow. She felt low in mood and was negative in her outlook. She was not formally thought disordered, and she was cognitively intact. She had insight into the deterioration of her mental state and agreed to informal admission to the hospital for assessment and treatment.

Admission blood tests were normal. She was not anemic, thyroid function tests were normal.

Initially on the ward, she appeared settled and was able to hold conversations with others. She was periodically anxious, requiring encouragement with food and drink intake. Due to her good response previously, the treatment team arranged a course of ECT during the admission, and she was deemed to have capacity to consent to the treatment. Prior to starting ECT, a 17-item Hamilton Rating Scale for Depression (HAM-D) was obtained, for which she scored 23, indicative of severe depression. A Mini-mental state examination (MMSE) was performed, when converted into Addenbrooke's Cognitive Examination III (ACE-III), gives 69–73/100. Clinical Global Impression Severity (CGIS) by the responsible clinician was rated 6 (severely ill).

ECT was performed with Thymatron System IV, using bitemporal electrode placement with a pulse width of 0.50 milliseconds. The details of each ECT session are summarised in Table 2 and Fig. 1.

Unfortunately, whilst on the ward, her clinical condition deteriorated. Her catatonia worsened considerably. She displayed virtually no interaction with external world. She showed mutism, fixed, non-reactive gaze. At times she would whisper ‘locked in,’ ‘I can’t’. She repeatedly exhibited a rocking motion of her torso with mild rigidity of her limbs. She was unable to be encouraged off her armchair and was unable to walk. She was unable to eat and drink, and was often unable to take oral medications. Prior to the second planned treatment, the team felt that she lacked capacity to consent to further sessions.

A Mental Health Act Assessment was arranged, and she was detained under Mental Health Act Section 2. Urgent ECT was prescribed under section 62, whilst a second opinion appointed doctor (SOAD) was sought for to grant her further ECT sessions. A total of 12 ECT sessions were granted.

After eight further sessions, the patient’s mental state did not improve. She continued to display minimal engagement. She often refused her medications, and her food and fluid intake was minimal. As a result, she underwent intravenous fluid therapy several times due to dehydration causing a deterioration of renal function. Treatment was given under Mental Health Act 1983 (amended 2007).

After 4th and 8th ECT sessions, repeated attempts were made by the ECT doctor to perform a MMSE, but she was deemed too unresponsive to answer the questions.

At the same time, several psychotropic medications were trialled. The date of their commencement and dose changes in relation to her ECT treatment are summarised in Table 3.

As a result of her lack of response to treatment, her diagnosis was reviewed and affirmed by the treatment team. Six further ECT sessions were granted through a Second Opinion Appointed Doctor (SOAD).

After 11 ECT sessions, she started to show signs of improvement. She started to walk around the ward and engage in various group activities. She started to accept her medications with less prompting. Her food and drink intake improved significantly, and she could eat independently. Her engagement with staff gradually improved, from making appropriate facial expressions to starting verbal communication. By the end of her ECT course, she could spontaneously engage in conversations and reported to us that ‘I am back.’ She was able to reflect on how severely unwell she was and felt ready to be discharged home. In view of her clinical improvement, ECT treatment was stopped. Extracts of clinical documentation on her progress have been summarized in Table 4.

The diagnosis was made during the admission – ICD-10 F32.3 severe depressive episode with psychotic symptoms [20]. She showed features of psychosis during the admission period. She frequently appeared guarded and suspicious, at time frightened. She at times reported that ‘people on the ward were not eating or drinking.’

Three months post-treatment, she scored 4 on HAMD, and scored 89–93/100 for ACE-III (converted from
| ECT session | BL/UL Mental Capacity | Dose<sup>a</sup> | Charge delivered (mC) | Current (A) | Frequency (Hertz) | Pulse width/ms | Stimulus duration/s | Seizure duration | Anaesthesia | Other information |
|-------------|-----------------------|------------------|----------------------|-------------|-------------------|---------------|---------------------|------------------|-------------|------------------|
| 1           | BL Consented          | 10% did not elicit adequate seizure. Increased to 15% | 75.9       | 0.90       | 20                | 0.50          | 4.2               | 19               | 21          | Propofol 90 mg Suxamethonium 40 mg 800 ml Hartmann’s solution IV given |
| 2           | BL Section 62         | 15%              | 75.7                 | 0.90       | 20                | 0.50          | 4.2               | 20               | 23          | Propofol 70 mg Suxamethonium 35 mg Unable to consent. Given under section 62 1 L Hartmann’s solution IV given |
| 3           | BL Section 62         | 15%              | 76.6                 | 0.91       | 20                | 0.50          | 4.2               | 20               | 31          | Propofol 80 mg Suxamethonium 40 mg 1 L Hartmann’s solution IV given |
| 4           | BL T6                | 25%              | 126.6                | 0.90       | 20                | 0.50          | 7.0               | 32               | 48          | Propofol 70 mg Suxamethonium 35 mg 800 ml Hartmann’s solution IV given |
| 5           | BL T6                | 25%              | 126.7                | 0.91       | 20                | 0.50          | 7.0               | 15               | 38          | Propofol 70 mg Suxamethonium 35 mg 1 L Hartmann’s solution IV given |
| 6           | BL T6                | 25% did not elicit visual seizure. Increased to 35% | 177.7      | 0.91       | 30                | 0.50          | 6.5               | Not observed      | 35          | Propofol 90 mg Suxamethonium 35 mg Unable to obtain MMSE due to severe catatonia. 500 ml Hartmann’s solution IV given |
| 7           | BL T6                | Increased to 55%, as no visual seizure in session 6 | 281.7      | 0.91       | 40                | 0.50          | 7.7               | 28               | 54          | Propofol 70 mg Suxamethonium 40 mg Difficult to engage prior to treatment due to distress and agitation 500 ml Hartmann’s solution IV given |
| 8           | BL T6                | 55%              | 288.2                | 0.94       | 40                | 0.50          | 7.7               | 18               | 35          | Propofol 80 mg Suxamethonium 35 mg Unable to obtain MMSE due to severe catatonia. 500 ml Hartmann’s solution IV given |
| 9           | BL T6                | 55%              | 280.3                | 0.91       | 40                | 0.50          | 7.7               | 25               | 41          | Propofol 80 mg Suxamethonium 40 mg |
| 10          | BL T6                | 55%              | 282.7                | 0.92       | 40                | 0.50          | 7.7               | 10               | 29          | Propofol 80 mg Suxamethonium 35 mg |
| 11          | BL T6                | 55%              | 282.3                | 0.92       | 40                | 0.50          | 7.7               | 10               | 14          | Propofol 80 mg Suxamethonium 40 mg 500 ml IV 0.9% saline given |
| 12          | BL T6                | 75%              | 379.0                | 0.90       | 60                | 0.50          | 7.0               | 20               | 30          | Propofol 80 mg Suxamethonium |
**Table 2** Details of ECT administration (Continued)

| ECT session | BL/UL | Mental Capacity | Dose \(^a\) | Charge delivered (mC) | Current (A) | Frequency (Hertz) | Pulse width/ms | Stimulus duration/s | Seizure duration | Anaesthesia | Other information |
|-------------|-------|-----------------|-------------|-----------------------|-------------|-------------------|---------------|-------------------|-----------------|-------------|------------------|
| 13          | BL    | T6              | 75%         | 378.0                 | 0.90        | 60                | 0.50          | 7.0               | 9               | 27          | 40 mg            |
| 14          | BL    | T6              | 75%         | 377.6                 | 0.90        | 60                | 0.50          | 7.0               | 20              | 26          | Propofol 80 mg Suxamethonium 40 mg |
| 15          | BL    | T6              | 75%         | 377.6                 | 0.90        | 60                | 0.50          | 7.0               | 5               | 19          | Propofol 80 mg Suxamethonium 40 mg |
| 16          | BL    | T6              | 75%         | 380.4                 | 0.91        | 60                | 0.50          | 7.0               | 11              | 33          | Propofol 100 mg Suxamethonium 40 mg |
| 17          | BL    | T6              | 75%         | 380.2                 | 0.91        | 60                | 0.50          | 7.0               | 15              | 17          | Propofol 100 mg Suxamethonium 40 mg |
| 18          |       |                 |             |                       |             |                   |               |                   |                 |             | Cancelled due to pyrexia of 37.7 C° pre-ECT. COVID-19 was suspected\(^b\). |

\(^a\)ECT dose at which a seizure response is visualised

\(^b\)2019-nCoV RNA Not Detected

BL/UL bilateral/unilateral temporal electrode placement, GTCS generalized tonic-clonic seizure, EEG electroencephalogram

---

**Fig. 1** ECT session visual and EEG seizure duration in s, charge delivered in mC.
MMSE). Clinical Global Improvement or change (CGI-C) was rated 1 (very much improved). Efficacy index was rated at 02 (vast improvement with side effects that do not significantly interfere with patient’s functioning).

Discussion and conclusion

We describe here a patient with a diagnosis of severe depression. She did not respond to electroconvulsive therapy until the 11th session, after which she had shown a drastic improvement in her mental state. The case is considered unusual. In the literature, the number of sessions during an acute course of ECT typically ranges from 6 to 12, usually given twice a week [4]. Early antidepressant effects of ECT is predictable of increased positive outcomes (6–7). Rarely, individuals with schizophrenia may require 12 to 20 sessions to elicit a response to treatment [5].

Compared to pharmacological treatment, ECT remains the most effective short-term treatment for patients with severe or treatment-resistant depression, with 70–90% of patients showing improvement [2]. In this case, a longer course of ECT has likely contributed to the patient’s response and remission.

There may be some debate surrounding the initiation of the ECT course in this patient. The empirical titration method aims to establish seizure threshold in the first session (titration session), and from session two onwards, therapeutic sessions are given with the stimulus at 1.5 times of the seizure threshold [8]. However, there has been questions surrounding the current threshold titration method of being too uncertain for valid optimisation or individualization of dose [21]. In this patient, the dose was not up-titrated, given the adequate seizure duration, good quality EEG fit during session one, balanced with potential cognitive side effect in this 75-year-old patient.

Other factors that might have contributed towards the improvement in this patient’s mental state includes a change in her medication regime. By the 10th session, she was taking three adjunctive pharmacological treatments including quetiapine, olanzapine, and lamotrigine. Quetiapine has demonstrated up to 48% response rate in combination with SSRIs and have been approved for adjunctive treatment of MDD by the Food and Drug Administration (FDA) [22]. Olanzapine, when combined specifically with fluoxetine, demonstrated 60% response amongst patients with treatment-resistant depression [23]. Lamotrigine is an anti-convulsive treatment that is currently licensed as an adjunctive therapy of bipolar disorder [24]. However, it was introduced by the treatment team following a lack of clinical response from the other agents and concurrent ECT treatment. Several studies have shown clinical improvement after augmentation with lamotrigine in treatment-resistant unipolar depression [25, 26].

The anti-epileptic effect of lamotrigine can theoretically inhibit the efficacy of ECT in inducing seizure activity. However, case reports/series have shown minimal or no influence on seizure and/or seizure duration [23]. In this patient, there was an increase in seizure threshold at session 12, with the introduction of lamotrigine being one possible contributing factor. However, it more than likely reflected the natural course of an ECT treatment regime. In addition, sertraline and olanzapine can theoretically lower seizure threshold, and some data have suggested beneficial and additive efficacy of second-generation antipsychotics (SGAs) to ECT, notably with clozapine [27].

The ECT Handbook of the Royal College of Psychiatrists stated that clinicians may wish to reassess the need for ECT if there is no response after six sessions. If there is no response within 12 treatment sessions, the patient is unlikely to have a ‘sustained response to ECT’ [8]. This patient displayed a delayed response, which is an

| Day of stay | ECT Session | Medication Changes |
|------------|-------------|--------------------|
| D1         | Session 1   | Sertraline increased to 150 mg OD |
| D4         | Session 2   | Sertraline increased to 200 mg OD |
| D11        | Session 3   | Quetiapine 50 mg BD |
| D14        | Session 4   | Quetiapine increased to 75 mg BD |
| D17        | Session 5   | Quetiapine increased to 100 mg BD |
| D22        | Session 6   | Lamotrigine 25 mg OD started |
| D24        | Session 7   | Lamotrigine increased to 50 mg OD |
| D25        | Session 8   | Lamotrigine increased to 75 mg OD |
| D28        | Session 9   | Lamotrigine increased to 100 mg OD |
| D31        | Session 10  | Lamotrigine increased to 75 mg OD |
| D34        | Session 11  | Lamotrigine to 100 mg OD |
| D35        | Session 12  | Lamotrigine increased to 50 mg OD |
| D36        | Session 13  | Lamotrigine increased to 75 mg OD |
| D39        | Session 14  | Lamotrigine increased to 100 mg OD |
| D42        | Session 15  | Lamotrigine increased to 75 mg OD |
| D45        | Session 16  | Lamotrigine to 100 mg OD |
| D46        | Session 17  | Lamotrigine to 100 mg OD |
| D49        | Session 18  | Lamotrigine to 100 mg OD |
| D53        | Session 19  | Lamotrigine to 100 mg OD |
| D56        | Session 20  | Lamotrigine to 100 mg OD |
| D60        | Session 21  | Lamotrigine to 100 mg OD |
| D63        | Session 22  | Lamotrigine to 100 mg OD |
| D67        | Session 23  | Lamotrigine to 100 mg OD |

Chen et al. BMC Psychiatry (2021) 21:50 Page 6 of 9
| ECT Session | Prior to ECT | Post ECT in recovery | Progress on the ward |
|------------|-------------|----------------------|----------------------|
| 1          | Settled, anxious at times, joined in with activities. Able to hold a conversation. Consented to ECT. Quiet on arrival, but did answer 4/5 orientation questions correctly | Anxious, quiet, but pleasant on approach. Compliant with medications | Reported to be highly anxious, kept saying 'no' or 'I don't know' – unable to give capacitous consent. Moderate evidence of psychomotor retardation and evolving mutism. Did not appear to be responding to unseen external stimuli. She required full support for her personal care |
| 2          | Unable to consent | On return to the ward, she refused medications, spat them out and had her mouth closed | Poor oral and fluid intake, received IV fluid treatment due to dehydration and deteriorating renal function |
| 3          | Very anxious and unable to answer any of the orientation questions | Able to drink full cup of squash and ate 2 biscuits. Completed 4/5 orientation questions | Upon returning to the ward, she became very anxious and hardly communicative. She was visibly shaking and humming |
| 4          | Very anxious and unable to answer any of the orientation questions | Had half a beaker of squash and IV Hartmann’s. Unable to obtain MMSE | Intermittent compliance with prescribed oral medication |
| 5          | Remained anxious and reluctant. Unable to answer any questions | Had some tea and biscuits – couldn’t answer orientation questions afterwards | Minimally interactive, and will respond with single words (no, no, no) |
| 6          | Had to be brought on a trolley due to high level of anxiety, distress and agitation | Had a mug of tea 290mls as well as 500 ml of Hartmann’s Fluid IV | She was having minimal conversation and continued to say ‘no, no, no.’ |
| 7          | Very anxious and was reluctant. Unable to answer any of the orientation questions | After the session, had tea, toast and biscuit. Conversed with staff about dieting, exercise and dogs | She has been keeping tablets in her mouth at times. Staff had to escort her to the toilet using a wheelchair |
| 8          | She had been variable in presentation. When she is less anxious, she could feed herself. Other times, she refused to eat and drink | She had been sat in the communal area post-ECT. | She returned to the ward with a smile. Then in the afternoon, she returned to the anxious state. She did manage all her meal |
| 9          | SOAD applied for 6 further ECT sessions | She was very calm, however did not interact with staff other than with short answers. She accepted a mug of tea and one and half slices of toast and marmalade. She was unable to answer any of the orientation questions | She has been out in the garden for a walk. She joined in the colouring group and participated well. Accepted medication with less prompting |
| 10         | She had been variable in presentation. When she is less anxious, she could feed herself. Other times, she refused to eat and drink | After the treatment, she was much calmer, however appeared confused at times. She had tea, cheddars and toast | She engaged well in physiotherapy strength and balance sessions |
| 11         | Calm. Did not answer any of the orientation questions. The only thing she said was ‘what is my name.’ She walked calmly back to the ward with staff | Accepted tea and toast. She was able to answer 2/5 of the orientation questions, however did say ‘my name used to be …’ | Eating and drinking well. Taking food in the canteen now, despite eating slowly. Minimal assistance required with personal care |
| 12         | Accepted tea and toast. She was able to answer 2/5 of the orientation questions, however did say ‘my name used to be …’ | She was able to tell us her name, date of birth, however followed each answer by ‘well it used to be’ | She had been settled and calm, spent time in communal area with others. She engaged well when spoken to and has not been making any noise. |
| 13         | She was able to walk to the clinic with a member of staff and answered 3/5 of the orientation questions. She became increasingly anxious when being prepared for ECT, however remained cooperative throughout | She was able to tell us her name and date of birth, however followed each answer by ‘well it used to be’ | When staff talked to her, she would always respond back with talking to staff. At times, she did smile to staff |
| 14         | She was able to tell us her name and date of birth, however followed each answer by ‘well it used to be’ | She was able to walk to the clinic with a member of staff and answered 3/5 of the orientation questions. She became increasingly anxious when being prepared for ECT, however remained cooperative throughout | Walked back to the ward with no concerns |
exception to the typical response pattern to ECT treatment for major depressive disorder. However, studies have shown the number of acute ECT treatments to be highly variable, and its efficacy is affected by a number of factors including treatment frequency [9], condition treated and its severity [10], the ECT pulse width [12] and electrode placement [13]. The concurrent use of pharmacological treatment for psychiatric and non-psychiatric conditions can also interact with ECT treatment [27]. This may call for a re-consideration of the ECT treatment regime, especially in cases where response may not have been observed by the later part of a treatment course. Moreover, further research is needed to help stratify and standardize the ECT treatment regime.

Abbreviations
ECT: Electroconvulsive therapy; HAM-D: Hamilton Rating Scale for Depression; CGIS: Clinical Global Impression severity; CGI-C: Clinical Global Improvement or Change; ICD-10: International Classification of Disease 10th revision; MDD: Major depressive disorder; MMSE: Mini-mental state examination; ACE-III: Addenbrooke’s Cognitive Examination III; SOAD: Second opinion appointed doctor; SGA: Second-generation anti-psychotics

Acknowledgements
We thank Dr. Ian Rowbotham (Cavell Centre, Peterborough) and Dr. Maheshi Wikramanayake (Cavell Centre, Peterborough) for the delivery of Electroconvulsive Therapy (ECT).

Authors’ contributions
FC was a major contributor in writing the manuscript, ES contributed to the manuscript revision and literature review, ER, JE, SY were involved in the clinical care of the patients above. All authors have corrected and approved the final manuscript.

Author’s information
Dr. Fangyue Chen was a foundation year one doctor at Peterborough City Hospital. Dr. Emad Sidhom is a Clinical Research Associate at University of Cambridge, Department of Clinical Neurosciences. Dr. Sharon Yang was a psychiatry trainee doctor at Older People's Mental Health, Cavell Centre, Peterborough. Dr. Eladia Ruiz-Mendoza is a consultant geriatrician at Peterborough City Hospital. Dr. Julius Essem is a consultant psychiatrist at Older People's Mental Health, Cavell Centre, Edith Cavell Hospital, Peterborough, UK.

Funding
This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent to publish the information was obtained from the patient. A copy of written consent is available for the journal.

Competing interests
None.

Author details
1Peterborough City Hospital, Bretton Gate, Peterborough, UK. 2Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. 3Older People’s Mental Health, Cavell Centre, Edith Cavell Hospital, Peterborough, UK.

Received: 25 August 2020 Accepted: 13 January 2021

Published online: 21 January 2021

Table 4 Patient progress on the ward as documented in the electronic note system (Continued)

| ECT Session | Prior to ECT | Post ECT in recovery | Progress on the ward |
|-------------|-------------|----------------------|----------------------|
| 17          | She was able to answer 3/5 of the orientation questions | She had cheddars and tea after the treatment. She completed 4/5 orientation questions and initiated the conversation briefly | She joined drama therapy group for the first time. Although she appeared quiet throughout the session, she contributed vocally and artistically to group exercises |
| 18          | ECT cancelled due to temperature of 37.7 °C | She was bright in mood, smiling more, playing dominos with other service users. Eating and drinking well. She could reflect on how severely unwell she was |

References
1. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–34 Available from: doi: 10.2147/NDT.S198774.
2. Lin CH, Chen MC, Yang WC, Lane HY. Early improvement predicts outcome of major depressive patients treated with electroconvulsive therapy. Eur Neuropsychopharmacol. 2016;26(2):225–33 Available from: doi: 10.1016/j.euroneuro.2015.12.019.
3. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007;357(19):1939–45 Available from: doi: 10.1056/NEJMct075234.
4. National Institute for Health and Care Excellence. Guidance on the use of electroconvulsive therapy [Internet]. London: NICE; 2003. [updated Oct 2009]. (Clinical guideline [TA59]). Available from: www.nice.org.uk/guidance/ta59.
5. Gangadhar BN, Thrallhj J. Frequency of electroconvulsive therapy sessions in a course. J ECT. 2010;26(3):181–5 Available from: doi: 10.1097/YCT.0b013e3181d66de.
6. Kendall RE. The present status of electroconvulsive therapy. Br J Psychiatry. 1981;139(4):265–83 Available from: doi: 10.1192/bjp.139.4.265.
7. Hausmann A, Post T, Post F, Dehning J, Kemmler G, Grunze H. Efficacy of continuation/maintenance electroconvulsive therapy in the treatment of patients with mood disorders: a retrospective analysis. J ECT. 2019;35(2): 122–6 Available from: doi: 10.1097/YCT.0000000000000547.
8. Waite J, Easton A, editors. The ECT handbook, 3rd edition. Cambridge: Royal College of Psychiatrists; 2013.
9. Shapira B, Tubi N, Lerer B. Balancing speed of response to ECT in major depressive disorder. Int J Neuropsychopharmacol. 2016;19(12):12 Available from: doi: 10.1097/YCT.0000000000000547.
10. Kho KH, Blansjaar BA, Vothknecht S, Cornelissen NMP, Koomen E, Zwinderman AH, Linszen DH. A study into predictors for the speed of response to electroconvulsive therapy. J ECT. 2004;20(3):154–9 Available from: doi: 10.1097/00124509-200406000-00002.
11. Van Diermen L, Van den Ameel S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, Birkenhager TK. Prediction of electroconvulsive therapy response and remission in major depression: Meta-analysis. Br J Psychiatry. 2018;212(2):71–80 Available from: doi: 10.1192/bjp.2017.28.
12. Colleen KL, Garfield JBB, Katalinic N, Schweitzer J, Hadzi-Pavlovic D. Speed of response in ultrabrief and brief pulse width right unilateral ECT. Int J

Page 8 of 9
13. Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997–2011. Acta Psychiatr Scand. 2014;129(6):417–26 Available from: doi: 10.1111/acps.12251.

14. Ittasakul P, Vora-aporn S, Waleepakhan P, Tor PC. Number of electroconvulsive therapy sessions required for Thai psychiatric patients: a retrospective study, vol. 16; 2020. p. 673–9. Available from: doi: 10.2147/NDT.S244031.

15. Chan CYW, Abdin E, Seow E, Subramaniam M, Liu J, Peh CX, Tor PC. Clinical effectiveness and speed of response of electroconvulsive therapy in treatment-resistant schizophrenia. 2019;73(7):416–22 Available from: doi: 10.1111/jcpp.13255.

16. Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry. 2004;65(4):485–91 Available from: doi: 10.4088/JCP.v65n0406.

17. Thirthalli J, Naik SS, Kunigiri G. Frequency and duration of course of ECT sessions: an appraisal of recent evidence. Indian J Psychol Med. 2020;42(3):207–18 Available from: doi:10.4103/IJPSYM.IJPSYM_410_19.

18. Tsuchiyama K, Nagayama H, Yamada K, Isoyama Katsuragi S, Kyota A. Predicting efficacy of electroconvulsive therapy in major depressive disorder. Psychiatry Clin Neurosci. 2005;59(5):46–50 Available from: doi: 10.1111/j.1440-1819.2005.01412.x.

19. Maoz H, Nitzan U, Goldwin Y, Krieger I, Bloch Y. How long should ECT course in adolescents last? A retrospective review. Brain Stimul. 2017;10(2):413 Available from: doi: 10.1016/j.brs.2017.01.226.

20. World Health Organization. International classification of diseases for mortality and morbidity statistics (10th version). 2019. Available from: https://icd.who.int/browse10/2019/en.

21. Rosenman SJ. Electroconvulsive therapy stimulus titration: Not all it seems. Aust N Z J Psychiatry. 2018;52(5):410–4 Available from: doi: 10.1177/0004867717743793.

22. Ruberto VL, Jha MK, Murrough JW. Pharmacological treatments for patients with treatment-resistant depression. Pharmaceutics (Basel). 2020;13(6):E116 Available from: doi: 10.3390/ph13060116.

23. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–4 Available from: doi: 10.1176/appi.ajp.158.1.131.

24. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press <http://www.medicinescomplete.com> [Accessed on [06/12/2020]].

25. Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Anghelescu K, Correll CU. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr. 2016;21(5):403–18 Available from: doi: 10.1017/S1092852916000523.

26. Goh KK, Chen CH, Chiu YH, Lu ML. Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. J Psychopharmacol. 2019;33(6):700–13 Available from: doi: 10.1177/026988119844199.

27. Zölezi. Medication management during electroconvulsant therapy. Neuropsychiatr Dis Treat. 2016;12:931–9 Available from: doi: 10.2147/NDT.S100908.